In the analysis related to all diabetes ICSRs, dapagliflozin was associated with a 12.7- and 7.6-fold increased reporting frequency of ketoacidosis adverse events compared to DPP-4is and insulin, respectively. This evidence concerns the gene INS and diabetes mellitus.